PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization
Journal of Experimental Medicine · 2026
DOI: 10.1084/jem.20252333 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2026. Verfasst von Hsin Chieh Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Cen…. Hauptthemen laut MEDLINE: Sumoylation, Promyelocytic Leukemia Protein, Retinoic Acid Receptor alpha, Hematopoietic Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National du Cancer, French National Research Agency, Paris St. Louis Leukemia Institute.
Abstract (Originalsprache)
While acute promyelocytic leukemia (APL) is always driven by fusions involving one of the three retinoic acid receptors, why PML and RARA are the preferred fusion partners has remained largely unsettled. Here, we demonstrate that corepressor (NCoR) binding onto the RARA moiety of PML::RARA is required for hematopoietic progenitor immortalization. We establish that PML-mediated tethering of the UBC9 SUMO-conjugating enzyme onto PML::RARA enforces SUMO2 conjugation of multiple RARA partner proteins, notably the NCoR complex, boosting its repressive power. PML mutants that fail to recruit UBC9 yield PML::RARA fusions that promote neither NCoR sumoylation nor transformation. Conversely, direct UBC9/RARA fusion drives both efficient corepressor complex sumoylation and immortalization. Sumoylation inhibitors reactivate retinoic acid target genes in PML::RARA-expressing, but not in RARA-expressing, progenitors and trigger APL differentiation. Thus, fusion of PML to RARA entails an unexpected gain of function that boosts RARA-mediated transcriptional repression through sumoylation of PML::RARA-bound proteins, explaining the recurrent implication of PML and RARA in APL pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée…
- Université Paris-Cité, Institut National de la Santé et de la Recherche Médicale U1342, Centre National de la Recherche Scientifique EMR8000, Institut de Recherche Saint-Louis, Hôpital Saint-Louis , Paris, France.
- Sorbonne Université, UMS 37 PASS, P3S, Institut National de la Santé et de la Recherche Médicale , Paris, France.
- Laboratoire d'hématologie Moléculaire, Assistance Publique-Hôpitaux de Paris, Hôpital St. Louis, Paris, France.
ORCID-Profile: Hsin Chieh Wu, Emmanuel Laplantine, Cécile Esnault, Michiko Niwa-Kawakita, Yi Zhang, Viviane De Almeida Bastos, Marie-Claude Geoffroy, Hugues de Thé
Förderung
- Institut National du Cancer
- French National Research Agency
- Paris St. Louis Leukemia Institute
- European Research Council
Zitieren
APA
Wu, H. C., Laplantine, E., Esnault, C., Niwa-Kawakita, M., Zhang, Y., De Almeida Bastos, V., Geoffroy, M. C., & de Thé, H. (2026). PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20252333
Vancouver
Wu HC, Laplantine E, Esnault C, Niwa-Kawakita M, Zhang Y, De Almeida Bastos V, et al. PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization. Journal of Experimental Medicine. 2026. doi:10.1084/jem.20252333
BibTeX
@article{Wu2026,
author = {Wu, Hsin Chieh and Laplantine, Emmanuel and Esnault, Cécile and Niwa-Kawakita, Michiko and Zhang, Yi and De Almeida Bastos, Viviane and Geoffroy, Marie-Claude and de Thé, Hugues},
title = {PML-driven sumoylation of PML::RARA-bound repressors drives hematopoietic progenitor immortalization},
journal = {Journal of Experimental Medicine},
year = {2026},
doi = {10.1084/jem.20252333}
}
EUVIMED